Coagulation abnormalities associated with CAR‐T‐cell therapy in haematological malignancies: A review

Summary Chimeric antigen receptor (CAR)‐T‐cell therapy has demonstrated considerable efficacy and safety in the treatment of patients with relapsed/refractory haematological malignancies. Owing to significant advances, CAR‐T‐cell therapeutic modality has undergone substantial shifts in its clinical application. Coagulation abnormalities, which are prevalent complications in CAR‐T‐cell therapy, can range in severity from simple abnormalities in coagulation parameters to serious haemorrhage or disseminated intravascular coagulation associated with life‐threatening multiorgan dysfunction. Nonetheless, there is a lack of a comprehensive overview concerning the coagulation abnormalities associated with CAR‐T‐cell therapy. With an aim to attract heightened clinical focus and to enhance the safety of CAR‐T‐cell therapy, this review presents the characteristics of the coagulation abnormalities associated with CAR‐T‐cell therapy, including clinical manifestations, coagulation parameters, pathogenesis, risk factors and their influence on treatment efficacy in patients receiving CAR‐T‐cell infusion. Due to limited data, these conclusions may undergo changes as more experience accumulates.